Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Serlopitant (Primary)
  • Indications Prurigo nodularis
  • Focus Therapeutic Use
  • Sponsors Menlo Therapeutics; Tigercat Pharma; Velocity Pharmaceutical Development
  • Most Recent Events

    • 25 Mar 2019 Results presented in a Menlo Therapeutics media release.
    • 17 Mar 2019 Results assessing safety and efficacy of Serlopitant for the treatment of prurigo nodularis published in the Journal of the American Academy of Dermatology
    • 29 Jan 2019 According to a Menlo Therapeutics media release, secondary analysis of this study will be presented at the Late-Breaking Research Program during the 2019 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top